Viewing StudyNCT03746431

Home Icon Home Search Icon Search Alerts Icon Stocks Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs eRecord Icon eRecord
Main Search All Studies All Organizations Report Bug
View Study With Definitions
Ignite Creation Date: 2024-05-06 @ 12:23 PM
Last Modification Date: 2024-10-26 @ 12:58 PM
Study NCT ID: NCT03746431
Status: RECRUITING
Last Update Posted: 2024-06-24
First Post: 2018-11-09
Brief Title: A Phase 12 Study of 225Ac-FPI-1434 Injection
Sponsor: Fusion Pharmaceuticals Inc
Organization: Fusion Pharmaceuticals Inc
Overview Dates Organization Conditions Design Enrollment Locations Outcomes

Conditions & Keywords Data

Conditions:
Name
Uveal Melanoma
Advanced Solid Tumours
Endometrial Cancer
Cervical Cancer
Ovarian Cancer
Breast Cancer
Triple Negative Breast Cancer TNBC
HER2-negative Breast Cancer
Head and Neck Squamous Cell Carcinoma HNSCC
Adrenocortical Carcinoma
Keywords:
Name View
Radiopharmaceuticals View
225-Ac Labelled Humanized Monoclonal Antibody Against IGF-1R View
225Ac-FPI-1434 View
IGF-IR Targeted Alpha Therapeutic View
IGF-IR Radioligand Therapy View